Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

68 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Regulation of the c-Abl and Bcr-Abl tyrosine kinases.
Hantschel O, Superti-Furga G. Hantschel O, et al. Nat Rev Mol Cell Biol. 2004 Jan;5(1):33-44. doi: 10.1038/nrm1280. Nat Rev Mol Cell Biol. 2004. PMID: 14708008 Review.
A myristoyl/phosphotyrosine switch regulates c-Abl.
Hantschel O, Nagar B, Guettler S, Kretzschmar J, Dorey K, Kuriyan J, Superti-Furga G. Hantschel O, et al. Cell. 2003 Mar 21;112(6):845-57. doi: 10.1016/s0092-8674(03)00191-0. Cell. 2003. PMID: 12654250
Structural basis for the autoinhibition of c-Abl tyrosine kinase.
Nagar B, Hantschel O, Young MA, Scheffzek K, Veach D, Bornmann W, Clarkson B, Superti-Furga G, Kuriyan J. Nagar B, et al. Cell. 2003 Mar 21;112(6):859-71. doi: 10.1016/s0092-8674(03)00194-6. Cell. 2003. PMID: 12654251
Structural basis for the cytoskeletal association of Bcr-Abl/c-Abl.
Hantschel O, Wiesner S, Güttler T, Mackereth CD, Rix LL, Mikes Z, Dehne J, Görlich D, Sattler M, Superti-Furga G. Hantschel O, et al. Mol Cell. 2005 Aug 19;19(4):461-73. doi: 10.1016/j.molcel.2005.06.030. Mol Cell. 2005. PMID: 16109371
Organization of the SH3-SH2 unit in active and inactive forms of the c-Abl tyrosine kinase.
Nagar B, Hantschel O, Seeliger M, Davies JM, Weis WI, Superti-Furga G, Kuriyan J. Nagar B, et al. Mol Cell. 2006 Mar 17;21(6):787-98. doi: 10.1016/j.molcel.2006.01.035. Mol Cell. 2006. PMID: 16543148
The Btk tyrosine kinase is a major target of the Bcr-Abl inhibitor dasatinib.
Hantschel O, Rix U, Schmidt U, Bürckstümmer T, Kneidinger M, Schütze G, Colinge J, Bennett KL, Ellmeier W, Valent P, Superti-Furga G. Hantschel O, et al. Proc Natl Acad Sci U S A. 2007 Aug 14;104(33):13283-8. doi: 10.1073/pnas.0702654104. Epub 2007 Aug 7. Proc Natl Acad Sci U S A. 2007. PMID: 17684099 Free PMC article.
Chemical proteomic profiles of the BCR-ABL inhibitors imatinib, nilotinib, and dasatinib reveal novel kinase and nonkinase targets.
Rix U, Hantschel O, Dürnberger G, Remsing Rix LL, Planyavsky M, Fernbach NV, Kaupe I, Bennett KL, Valent P, Colinge J, Köcher T, Superti-Furga G. Rix U, et al. Blood. 2007 Dec 1;110(12):4055-63. doi: 10.1182/blood-2007-07-102061. Epub 2007 Aug 24. Blood. 2007. PMID: 17720881
Characterization of BCR-ABL deletion mutants from patients with chronic myeloid leukemia.
Sherbenou DW, Hantschel O, Turaga L, Kaupe I, Willis S, Bumm T, Press RD, Superti-Furga G, Druker BJ, Deininger MW. Sherbenou DW, et al. Leukemia. 2008 Jun;22(6):1184-90. doi: 10.1038/leu.2008.65. Epub 2008 Mar 20. Leukemia. 2008. PMID: 18354488
Target spectrum of the BCR-ABL inhibitors imatinib, nilotinib and dasatinib.
Hantschel O, Rix U, Superti-Furga G. Hantschel O, et al. Leuk Lymphoma. 2008 Apr;49(4):615-9. doi: 10.1080/10428190801896103. Leuk Lymphoma. 2008. PMID: 18398720 Review.
68 results
Jump to page
Feedback